O. Kisker

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Alberto Sobrero, Joan Maurel, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2008 · 945 citations · Full text

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Eric Van Cutsem, István Láng, G D’Haens et al. · Journal of Clinical Oncology · 2008 · 373 citations

Surgical Oncology, Cancer Management, Pathology +20

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Josep Tabernero, Eric Van Cutsem, Eduardo Díaz‐Rubio et al. · Journal of Clinical Oncology · 2007 · 337 citations

Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase

Angelina J. Lay, Xing‐Mai Jiang, O. Kisker et al. · Nature · 2000 · 268 citations

Cancer Research, Signal Transduction, Angiogenesis +10

Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.

O. Kisker, C.-M. Becker, Daniela Prox et al. · PubMed · 2001 · 258 citations

Immunology, Continuous Administration, Pharmacotherapy +16